➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Dow
Colorcon
Baxter
Mallinckrodt

Last Updated: June 1, 2020

DrugPatentWatch Database Preview

Patent: 8,114,628

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,114,628
Title:Expanding the eukaryotic genetic code
Abstract: This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells are also provided.
Inventor(s): Chin; Jason W. (Cambridge, GB), Cropp; T. Ashton (Bethesda, MD), Anderson; J. Christopher (San Francisco, CA), Schultz; Peter G. (La Jolla, CA)
Assignee: The Scripps Research Institute (La Jolla, CA)
Application Number:11/978,121
Patent Claims:see list of patent claims

Details for Patent 8,114,628

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Lilly HUMULIN R insulin recombinant human INJECTABLE;INJECTION 018780 001 1982-12-02   Start Trial The Scripps Research Institute (La Jolla, CA) 2023-04-17 RX search
Lilly HUMULIN R KWIKPEN insulin human SOLUTION;SUBCUTANEOUS 018780 002 1982-12-02   Start Trial The Scripps Research Institute (La Jolla, CA) 2023-04-17 RX search
Lilly HUMULIN R insulin human SOLUTION;SUBCUTANEOUS 018780 004 1982-12-02   Start Trial The Scripps Research Institute (La Jolla, CA) 2023-04-17 RX search
Lilly HUMULIN R PEN insulin recombinant human INJECTABLE;INJECTION 018780 005 1982-12-02   Start Trial The Scripps Research Institute (La Jolla, CA) 2023-04-17 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Mallinckrodt
AstraZeneca
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.